✦ LIBER ✦

Bevacizumab in combination with paclitaxel for HER-2 negative metastatic breast cancer: An economic evaluation

✍ Scribed by Konstantin J. Dedes; Klazien Matter-Walstra; Matthias Schwenkglenks; Bernhard C. Pestalozzi; Daniel Fink; Peter Brauchli; Thomas D. Szucs

Book ID: 116429930
Publisher: Elsevier Science
Year: 2009
Tongue: English
Weight: 718 KB
Volume: 45
Category: Article
ISSN: 0959-8049
DOI: 10.1016/j.ejca.2008.12.016

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Paclitaxel and bevacizumab in first-line

Paclitaxel and bevacizumab in first-line treatment for HER2-negative metastatic breast cancer: single-center experience

✍ Lorenzo Livi, Pierluigi Bonomo, Icro Meattini, Gabriele Simontacchi, Daniela Gre 📂 Article 📅 2013 🏛 Springer US 🌐 English ⚖ 170 KB

Metronomic Chemotherapy Combined With Be

Metronomic Chemotherapy Combined With Bevacizumab and Erlotinib in Patients With Metastatic HER2-Negative Breast Cancer: Clinical and Biological Activity

✍ Emilia Montagna; Giuseppe Cancello; Vincenzo Bagnardi; Davide Pastrello; Silvia 📂 Article 📅 2012 🏛 CIG Media Group, LP. 🌐 English ⚖ 488 KB

Final results of a phase II study ofnab-

Final results of a phase II study ofnab-paclitaxel, bevacizumab, and gemcitabine as first-line therapy for patients with HER2-negative metastatic breast cancer

✍ Christopher Lobo; Gilberto Lopes; Odalys Baez; Aurelio Castrellon; Annapoorna Fe 📂 Article 📅 2010 🏛 Springer US 🌐 English ⚖ 268 KB

Motesanib, or open-label bevacizumab, in

Motesanib, or open-label bevacizumab, in combination with paclitaxel, as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: a phase 2, randomised, double-blind, placebo-controlled study

✍ Miguel Martin; Henri Roche; Tamas Pinter; John Crown; M John Kennedy; Louise Pro 📂 Article 📅 2011 🏛 The Lancet 🌐 English ⚖ 230 KB

Safety results from a phase III study (T

Safety results from a phase III study (TURANDOT trial by CECOG) of first-line bevacizumab in combination with capecitabine or paclitaxel for HER-2-negative locally recurrent or metastatic breast cancer

✍ I. Lang; M.J. Inbar; Z. Kahán; R. Greil; S. Beslija; S.M. Stemmer; B. Kaufman; Z 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 302 KB

A Phase II Trial of Docetaxel With Bevac

A Phase II Trial of Docetaxel With Bevacizumab as First-line Therapy for HER2-Negative Metastatic Breast Cancer (TORI B01)

✍ Sara A. Hurvitz; Heather J. Allen; Rebecca L. Moroose; David Chan; Christopher H 📂 Article 📅 2010 🏛 CIG Media Group, LP. 🌐 English ⚖ 598 KB